摘要
目的观察急性缺血性脑卒中应用尤瑞克林联合依达拉奉治疗的安全性与临床效果。方法将我院2013年6月至2014年2月收治的46例急性缺血性脑卒中患者随机分为治疗组与对照组,每组23例。治疗组给予尤瑞克林联合依达拉奉注射液静脉滴注治疗,对照组给予依达拉奉注射液静脉滴注治疗。治疗前后分别采用脑卒中量表(NIHSS)进行临床疗效评价,并于治疗前后对两组患者的血清VEGF、超敏C反应蛋白及S100B的水平进行测量,严密监测治疗过程中患者肝肾功能、血尿常规以及血脂等指标的变化,并做好不良反应记录。结果两组患者治疗前NIHSS评分情况比较差异无统计学意义(P>0.05)。治疗后,两组的NIHSS评分均显著降低,与治疗前比较差异有统计学意义(P<0.05),且治疗组NIHSS评分低于对照组,差异有统计学意义(P<0.05)。经疗效判定,治疗组的临床疗效明显优于对照组,两组比较差异有统计学意义(P<0.05)。治疗前,两组患者血清VEGF、超敏C蛋白及S100B含量比较差异无统计学意义(P>0.05);治疗后,治疗组患者血清VEGF含量高于对照组,血清超敏C蛋白、S100B含量低于对照组,差异均有统计学意义(P<0.05)。结论尤瑞克林联合依达拉奉治疗急性缺血性脑卒中能够有效改善患者的神经功能缺损情况,提高患者血液中VEGF的水平,使超敏C反应蛋白及S100B的含量显著降低,有较高的安全性,并有助于提高患者的生活质量。
Objective To investigate the efficacy and safety of the combination of urinary kallikrein and edar-avone injection in the treatment of acute ischemic stroke. Methods Forty-six patients with acute ischemic stroke were recruited from June 2013 to February 2014 and randomly divided into treatment group（ both urinary kallikrein and edar-avone injection） and control group（only edaravone injection）. National Institute of Health stroke scale （NIHSS） was employed to evaluate the clinical efficacy,and the levels of serum VEGF,high-sensitivity C-reactive protein and S100B were measured. The liver and kidney functions were monitored by blood tests,the potential side effects were recor-ded. Results There was no significant difference in NIHSS scores between the two groups before treatment （ P 〉0. 05）. After treatment,NIHSS scores in both groups decreased significantly （P 〈0. 05）,and NIHSS scores in treat-ment group were significantly lower than those of control group （ P〈0. 05 ） . The serum level of VEGF in treatment group was higher than that of control group,and the levels of super-sensitivity C-protein and S100B were significantly lower （ P〈0. 05 ） . Conclusion The joint treatment of urinary kallikrein and edaravone injection could improve the neurological deficits of patients with acute ischemic stroke,elevate the serum level of VEGF and lower the levels of high sensitivity C-reactive protein and S100B. It is safe and helpful to improve the life quality of patients with acute is-chemic stroke.
出处
《实用药物与临床》
CAS
2015年第10期1164-1167,共4页
Practical Pharmacy and Clinical Remedies
基金
国家自然科学青年基金(81200834)
辽宁省自然科学基金(2013021070)
沈阳市科学技术计划项目(F10-205-1-10)
